Reports Q3 revenue $230.5M vs. $242.80M a year ago. CEO Travis Dalton said, “During Q3, we experienced growth in volumes of billed charges and identified potential savings. Our Revenues and Adjusted EBITDA were in line with the low end of our guidance for Q3. We are tightening our Revenues guidance with a modest decrease to the top end of our Adjusted EBITDA guidance for full year 2024. We anticipate Q4 to run similar to our Q3. As I shared with our Q2 earnings results, I remain confident in this Company and its transformation journey. With the building of my leadership team nearly complete, this talented team has already marched forward to clearly establish the framework for developing a data and insights driven and technology focused company that is fit for growth…Our multi-year transformation towards a world-class data and technology company is underway. We will work with all stakeholders of the healthcare continuum to positively impact increased transparency, improved quality and lower costs. This focus will provide the platform for our long-term sustainable growth. I look forward to sharing the big mileposts of our transformation journey in the months and quarters to come.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter